Drugs / SEΔΔΔ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04731259 | Jan 2024 → Jan 2026 | rosacea | Azitra Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEΔΔΔ | “ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.” NCT04731259 ↗ |
| Modality | Other / unclassified | “a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine” NCT04731259 ↗ |
| Route | Topical | “The intervention is an ointment that will be applied topically BID for 28 days.” NCT04731259 ↗ |